Gupchup G V, Wolfgang A P, Thomas J
College of Pharmacy, University of New Mexico, Albuquerque, USA.
Clin Ther. 1997 Sep-Oct;19(5):1116-25. doi: 10.1016/s0149-2918(97)80064-1.
To render quality-of-life scores on an instrument acceptable for cross-national comparison, the instrument's reliability and validity must be established in all countries in question. The Asthma Quality of Life Questionnaire-Marks (AQLQ-M) was developed in Australia, where it was shown to have good reliability and validity. However, no attempt had been made to determine the psychometric properties of the AQLQ-M and its domains (i.e., Breathlessness, Mood, Social, and Concerns) in the United States. The objectives of the present study were to administer the AQLQ-M to a sample of adult asthmatic patients in the United States (N = 106) and assess (1) the acceptability of the AQLQ-M to respondents, (2) the internal consistency of the AQLQ-M and its domains, and (3) the construct validity of the AQLQ-M and its domains. Results indicated that respondents did not have difficulty answering the questions in the AQLQ-M. The Cronbach coefficient alpha value for the AQLQ-M was 0.94. The Cronbach coefficient alpha value for individual domains ranged from 0.84 to 0.91, providing evidence of good internal consistency reliability for the AQLQ-M and its domains. Pearson product-moment correlations between the domain scores ranged from 0.62 to 0.88, indicating that the domains were related but separate aspects of asthma-specific quality of life, as measured by the AQLQ-M. Spearman rank-order correlations of the AQLQ-M score and domain scores with an indicator of disease severity--number of different prescription medications taken for asthma in the preceding 3 months-were positive and significant. This indicated that subjects taking a greater number of prescription asthma medications had higher AQLQ-M and domain scores, or a greater negative impact of asthma on quality of life, a result consistent with previous findings and one that provides some evidence of convergent validity. Our findings support the use of the AQLQ-M as a decision-making tool in the United States and in cross-national comparisons between the United States and Australia.
为使某一量表上的生活质量得分适用于跨国比较,必须在所有相关国家确定该量表的信度和效度。哮喘生活质量问卷-马克斯版(AQLQ-M)是在澳大利亚编制的,在该国显示出良好的信度和效度。然而,尚未有人尝试在美国确定AQLQ-M及其维度(即呼吸急促、情绪、社交和担忧)的心理测量特性。本研究的目的是对美国的成年哮喘患者样本(N = 106)进行AQLQ-M测试,并评估:(1)AQLQ-M对受访者的可接受性;(2)AQLQ-M及其维度的内部一致性;(3)AQLQ-M及其维度的结构效度。结果表明,受访者回答AQLQ-M中的问题没有困难。AQLQ-M的克朗巴赫系数α值为0.94。各个维度的克朗巴赫系数α值在0.84至0.91之间,为AQLQ-M及其维度的良好内部一致性信度提供了证据。维度得分之间的皮尔逊积差相关系数在0.62至0.88之间,表明这些维度是哮喘特异性生活质量的相关但不同的方面,这是通过AQLQ-M测量得出的。AQLQ-M得分和维度得分与疾病严重程度指标(前3个月用于治疗哮喘的不同处方药数量)的斯皮尔曼等级相关呈正且显著。这表明服用更多哮喘处方药的受试者AQLQ-M得分和维度得分更高,即哮喘对生活质量的负面影响更大,这一结果与先前的研究结果一致,也为收敛效度提供了一些证据。我们的研究结果支持在美国以及美国与澳大利亚之间的跨国比较中使用AQLQ-M作为决策工具。